NF2 and schwannomatosis: The best practice would be to develop a COS that is specific to NF2-schwannomatosis, which utilizes the NF2-schwannomatosis literature and includes representative stakeholders, including patients with NF2-schwannomatosis to develop a COS that includes outcomes that are most relevant to this unique patient population.